The Walter and Eliza Hall Institute of Medical Research

Amrad Operations Pty Ltd

Zenyth Operations Pty. Ltd.

Warren S Alexander

Nicos Anthony Nicola

Douglas James Hilton

Tracy Ann Willson

Donald Metcalf

Sandra Elaine Nicholson

Rachael T Richardson

Robyn Starr

Elizabeth M Viney

Timothy Gainsford

Ashley Ng

Jian-Guo Zhang

Alison Farley

Manuel Baca

Andrew Donald Nash

Richard John Simpson

Tetsuo Kojima

Louis Jerry Fabri

Yasufumi Kikuchi

Steven Rakar

Masatsugu Maeda

The present invention relates generally to therapeutic and diagnostic agents. More particularly, the present invention provides therapeutic molecules capable of modulating signal transduction such as but not limited to cytokine-mediated signal transduction. The molecules of the present invention are useful, therefore, in modulating cellular responsiveness to cytokines as well as other mediators of signal transduction such as endogenous or exogenous molecules, antigens, microbes and microbial products, viruses or components thereof, ions, hormones and parasites.

Therapeutic and diagnostic agents

The present invention relates generally to a novel haemopoietin receptor or derivatives thereof and to genetic sequences encoding same. Interaction between the novel receptor of the present invention and a cytokine ligand facilitates proliferation, differentiation and survival of a wide variety of cells. The novel receptor and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor.

Haemopoietin receptor and genetic sequence encoding same

The present invention relates generally to amino acid sequences obtainable from SOCS proteins and which are capable of interacting with intracellular molecules. The present invention further relates to nucleic acid molecules encoding said amino acid sequences. The amino acid sequences and the nucleic acid molecules encoding same of the present invention are useful in modulating degradation of proteinaceous molecules such as but not limited to SOCS proteins and proteinaceous molecules associated therewith. The present invention provides a mechanism for modulating cytokine or cytokine-like molecule signalling by modulating the degradation of activated signal transduction molecules or their negative regulators, i.e. the SOCS proteins.

Screening methods using SOCS box-containing peptides

Therapeutic and diagnostic agents comprising a SOCS box

The present invention is directed to a novel haemopoietin receptor or a derivative thereof and to genetic sequences encoding same. The receptor molecule and its derivatives and the genetic sequences encoding same of the present invention are useful in the development of a wide range of agonists, antagonists, therapeutics and diagnostic reagents based on ligand interaction with its receptor. The present invention particularly relates to a receptor for leptin.

Haemopoietin receptor and genetic sequences encoding same

Therapeutic and diagnostics proteins comprising a SOCS box

Growing community of inventors

Moonee Ponds, Australia

Warren S Alexander